Medicare Part D drugs starting with R
82 drugs start with R; 40 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Revlimid in 2024: $4.2 billion, what plans and patients paid at the pharmacy before rebates.
Which drugs start with R?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| RabAvert (rabies vaccine) | 100% | Tier 1 | $1 million |
| Rabeprazole sodium | 73.7% | Tier 2 | $13 million |
| Radicava (edaravone) | 31.4% | Tier 5 | $5 million |
| Raldesy (trazodone hydrochloride) | 100% | Tier 4 | no 2024 match |
| Raloxifene hydrochloride | 100% | Tier 2 | $32 million |
| Ramelteon | 71% | Tier 4 | $24 million |
| Ramipril | 100% | Tier 1 | $17 million |
| Ranitidine | 0.5% | Tier 1 | no 2024 match |
| Ranolazine | 100% | Tier 4 | $111 million |
| Rasagiline | 100% | Tier 4 | $28 million |
| Rasuvo (methotrexate) | 6.2% | Tier 4 | $22 million |
| Rayaldee (calcifediol) | 29.3% | Tier 5 | $43 million |
| Rebif (interferon beta-1a) | 6.2% | Tier 5 | $105 million |
| Reclipsen (desogestrel / ethinyl estradiol) | 96.6% | Tier 2 | $7 thousand |
| Recombivax (hepatitis B vaccine) | 100% | Tier 1 | no 2024 match |
| Recorlev (levoketoconazole) | 2.6% | Tier 5 | $30 million |
| Rectiv (nitroglycerin) | 1% | Tier 4 | $2 million |
| Redemplo (plozasiran) | 1.2% | Tier 5 | no 2024 match |
| Reglan (metoclopramide) | under 0.1% | Tier 1 | $68 thousand |
| Relenza (zanamivir) | 87.1% | Tier 4 | $13 thousand |
| Releuko (filgrastim-ayow) | 4.1% | Tier 4 | $92 thousand |
| Relexxii (methylphenidate hydrochloride) | 0.1% | Tier 3 | $39 thousand |
| Relistor (methylnaltrexone bromide) | 25.4% | Tier 5 | $135 million |
| Remeron (mirtazapine) | under 0.1% | Tier 1 | $732 thousand |
| Repaglinide | 100% | Tier 1 | $12 million |
| Repatha (evolocumab) | 92.8% | Tier 3 | $1.9 billion |
| Restasis (cyclosporine) | 59.7% | Tier 3 | $1.3 billion |
| Retacrit (epoetin alfa-epbx) | 54.3% | Tier 4 | $27 million |
| Retevmo (selpercatinib) | 100% | Tier 5 | $85 million |
| Retin-A (tretinoin) | 2.3% | Tier 2 | $1 million |
| Retrovir (zidovudine) | 0.2% | Tier 1 | no 2024 match |
| Revcovi (elapegademase-lvlr) | 100% | Tier 5 | $40 million |
| Revlimid (lenalidomide) | 3.5% | Tier 5 | $4.2 billion |
| Revuforj (revumenib) | 100% | Tier 5 | $1 million |
| Rextovy (naloxone hydrochloride) | 44.8% | Tier 4 | no 2024 match |
| Rexulti (brexpiprazole) | 100% | Tier 5 | $861 million |
| Reyataz (atazanavir) | 100% | Tier 5 | $650 thousand |
| Rezdiffra (resmetirom) | 100% | Tier 5 | $69 million |
| Rezlidhia (olutasidenib) | 100% | Tier 5 | $15 million |
| Rezurock (belumosudil) | 52.5% | Tier 5 | $243 million |
Show the other 42 drugs
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Rezvoglar (insulin glargine-aglr) | 1.1% | Tier 2 | $586 thousand |
| Rhapsido (remibrutinib) | 0.3% | Tier 5 | no 2024 match |
| Rhopressa (netarsudil) | 91.4% | Tier 3 | $168 million |
| Ribavirin | 100% | Tier 3 | $246 thousand |
| Ridaura (auranofin) | 15.2% | Tier 3 | $922 thousand |
| Rifabutin | 100% | Tier 4 | $7 million |
| Rifampin | 100% | Tier 3 | $7 million |
| Riluzole | 100% | Tier 4 | $8 million |
| Rimantadine hydrochloride | 89.1% | Tier 4 | $126 thousand |
| Rinvoq (upadacitinib) | 98.2% | Tier 5 | $1.4 billion |
| Risedronate sodium | 88.6% | Tier 3 | $26 million |
| Risperdal (risperidone) | 26.5% | Tier 4 | $4 million |
| Risperidone | 100% | Tier 2 | $97 million |
| Ritalin (methylphenidate hydrochloride) | 0.2% | Tier 1 | $1 million |
| Ritonavir | 100% | Tier 3 | $6 million |
| Rivaroxaban | 89.4% | Tier 3 | no 2024 match |
| Rivastigmine | 100% | Tier 2 | $89 million |
| Rivelsa (ethinyl estradiol) | 30.3% | Tier 2 | $4 thousand |
| Rivfloza (nedosiran) | 3.8% | Tier 5 | no 2024 match |
| Rizatriptan | 98.8% | Tier 2 | $15 million |
| Rocaltrol (calcitriol) | under 0.1% | Tier 1 | $17 thousand |
| Rocklatan (latanoprost / netarsudil) | 89.5% | Tier 3 | $167 million |
| Roflumilast | 100% | Tier 4 | $32 million |
| Romvimza (vimseltinib) | 100% | Tier 5 | no 2024 match |
| Ropinirole | 100% | Tier 2 | $65 million |
| Rosuvastatin calcium | 100% | Tier 1 | $437 million |
| Rosyrah (ethinyl estradiol) | 41.5% | Tier 2 | no 2024 match |
| Rotarix (rotavirus vaccine) | 100% | Tier 1 | no 2024 match |
| RotaTeq (rotavirus vaccine) | 100% | Tier 1 | no 2024 match |
| Rowasa (mesalamine) | 0.3% | Tier 4 | $44 thousand |
| Roweepra (levetiracetam) | 93.9% | Tier 2 | $749 |
| Roxicodone (oxycodone hydrochloride) | under 0.1% | Tier 1 | $2 million |
| Rozerem (ramelteon) | under 0.1% | Tier 1 | $735 thousand |
| Rozlytrek (entrectinib) | 100% | Tier 5 | $19 million |
| Rubraca (rucaparib) | 100% | Tier 5 | $32 million |
| Ruconest (C1 esterase inhibitor, recombinant) | 0.1% | Tier 6 | $56 million |
| Rufinamide | 100% | Tier 4 | $30 million |
| Rukobia (fostemsavir) | 100% | Tier 5 | $115 million |
| Ryaltris (mometasone furoate / olopatadine hydrochloride) | 20.3% | Tier 4 | $3 million |
| Rybelsus (semaglutide) | 93.8% | Tier 3 | $1.9 billion |
| Rydapt (midostaurin) | 100% | Tier 5 | $27 million |
| Rytary (carbidopa / levodopa) | 12% | Tier 4 | $272 million |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans